TY - JOUR
T1 - Alternative monotherapy or add-on therapy in patients with epilepsy whose seizures do not respond to the first monotherapy
T2 - An Italian multicenter prospective observational study
AU - Millul, Andrea
AU - Iudice, Alfonso
AU - Adami, Marina
AU - Porzio, Roberto
AU - Mattana, Flavia
AU - Beghi, Ettore
PY - 2013/9
Y1 - 2013/9
N2 - A prospective multicenter observational study was undertaken on children and adults with epilepsy in whom first monotherapy failed, to assess indications and effects of alternative monotherapy vs. polytherapy. Patients were followed until 12-month remission, drug withdrawal, or up to 18. months. Monotherapy and polytherapy were compared for patients' baseline features, indication, retention time, remission, adverse events (AE), quality of life, and direct and indirect costs. Included were 157 men and 174 women, aged 2-86. years. Of the patients, 72.2% were switched to alternative monotherapy. Baseline treatment was changed for lack of efficacy (73.9%) or adverse events (26.1%). Two hundred forty-three completed the study (remission: 175; 72.0%). Retention time, hospital admissions, days off-work and off-school, and quality of life did not differ between the two treatment groups. Patients were followed for 365.3. person-years. Three hundred eighty-three incident AEs were reported by 46.4% of patients in monotherapy and 40.2% in polytherapy (serious AEs: 9.6% vs. 8.7%, mostly nondrug-related).
AB - A prospective multicenter observational study was undertaken on children and adults with epilepsy in whom first monotherapy failed, to assess indications and effects of alternative monotherapy vs. polytherapy. Patients were followed until 12-month remission, drug withdrawal, or up to 18. months. Monotherapy and polytherapy were compared for patients' baseline features, indication, retention time, remission, adverse events (AE), quality of life, and direct and indirect costs. Included were 157 men and 174 women, aged 2-86. years. Of the patients, 72.2% were switched to alternative monotherapy. Baseline treatment was changed for lack of efficacy (73.9%) or adverse events (26.1%). Two hundred forty-three completed the study (remission: 175; 72.0%). Retention time, hospital admissions, days off-work and off-school, and quality of life did not differ between the two treatment groups. Patients were followed for 365.3. person-years. Three hundred eighty-three incident AEs were reported by 46.4% of patients in monotherapy and 40.2% in polytherapy (serious AEs: 9.6% vs. 8.7%, mostly nondrug-related).
KW - Cohort study
KW - Epilepsy
KW - Monotherapy
KW - Polytherapy
UR - http://www.scopus.com/inward/record.url?scp=84880941008&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880941008&partnerID=8YFLogxK
U2 - 10.1016/j.yebeh.2013.05.038
DO - 10.1016/j.yebeh.2013.05.038
M3 - Article
C2 - 23892580
AN - SCOPUS:84880941008
VL - 28
SP - 494
EP - 500
JO - Epilepsy and Behavior
JF - Epilepsy and Behavior
SN - 1525-5050
IS - 3
ER -